Galactose (DrugBank: Galactose)
2 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 171 | ウィルソン病 | 1 |
| 222 | 一次性ネフローゼ症候群 | 4 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02702765 (ClinicalTrials.gov) | February 2016 | 26/2/2016 | sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis | Macrophages and the Macrophage Activation Markers sCD163 and Mannose Receptor (sMR) in Patients With Wilsons Disease - Associations With Liver Disease Severity and Fibrosis | Wilsons Disease | Procedure: Fibroscan;Procedure: Ultrasound;Drug: Galactose;Procedure: Liver biopsy;Procedure: Functional hepatic nitrogen clearance | University of Aarhus | Aarhus University Hospital | Active, not recruiting | 18 Years | 100 Years | All | 33 | N/A | Denmark |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01113385 (ClinicalTrials.gov) | October 2009 | 28/4/2010 | Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome | Effect of Oral Galactose on the Level of Focal Sclerosis Permeability Factor and Proteinuria in Children With Steroid Resistant Nephrotic Syndrome: A Pilot Study | Focal Segmental Glomerulosclerosis;Steroid Resistant Nephrotic Syndrome | Drug: D-Galactose | Children's Research Institute | National Kidney Foundation | Completed | 2 Years | 21 Years | All | 7 | N/A | United States |
| 2 | NCT00816478 (ClinicalTrials.gov) | December 2008 | 31/12/2008 | Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor | Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS) | Focal Segmental Glomerulosclerosis | Drug: Galactose | North Shore Long Island Jewish Health System | NULL | Terminated | 2 Years | 60 Years | Both | 15 | Phase 1 | United States |
| 3 | NCT00814255 (ClinicalTrials.gov) | December 2008 | 22/12/2008 | Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial | Novel Therapies for Resistant Focal Segmental Glomerulosclerosis | Focal Segmental Glomerulosclerosis | Drug: Adalimumab;Drug: Lisinopril, losartan, and atorvastatin;Drug: galactose | New York University School of Medicine | University of Michigan;The Cleveland Clinic;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | 1 Year | 65 Years | All | 32 | Phase 2 | United States;Canada |
| 4 | NCT00816504 (ClinicalTrials.gov) | December 2008 | 31/12/2008 | Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5 | Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS)and Chronic Kidney Disease Stage 5 | Focal Segmental Glomerulosclerosis | Drug: Galactose | North Shore Long Island Jewish Health System | Medical College of Wisconsin | Withdrawn | 2 Years | 60 Years | Both | 0 | Phase 1 | United States |